Cancer Vaccine Clinical Trials Workshop

Program Co-Chairs:

Axel Hoos, MD, PhD
Antigenics
Lexington, MA

Geoffrey Nichol, MD
Medarex, Inc
Bloomsbury, NJ

Giorgio Parmiani, MD
Istituto Nazionale Tumori
Milan, Italy

Mario Sznol, MD
Yale University School of Medicine
New Haven, CT

Invited Faculty:

Chris Beattie, MBA
ONYVAX LTD
London, United Kingdom

Vance Berger
NCI, Div. Cancer Prevention
Bethesda, MD

Neil Berinstein, MD
Aventis Pasteur
Toronto, ON Canada

Brent A. Blumenstein, PhD
TriArc Consulting
Seattle, WA

Flavia Borellini, PhD
Cell Genesys
South San Francisco, CA

Vincent Brichard, MD, PhD
GlaxoSmithKline Biologicals
Rixensart, Belgium

Peter Bross, MD
FDA- Office Cellular, Tissue, Gene Therapies
Rockville, MD

Taylor Burtis, MBA
Therion Biologics Corporation
Cambridge, MA

Vincenzo Cerundolo, MD, PhD
University of Oxford - Inst. of Molec. Medicine
Oxford, United Kingdom

Paul B. Chapman, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

David N. Cook, PhD
Cerus Corporation
Concord, CA

Alexander M. Eggermont, MD, PhD
Erasmus University Medical Center
Rotterdam, Netherlands

Guy Ely, MD
BioMira, Inc.
Edmonton, AB Canada

Bernard Escudier, MD
Institut Gustave Roussy
Villejuif, Cedex France

Steven Fischkoff, MD
Medarex, Inc.
Bloomsbury, NJ

Mark Frohlich, MD
Xcyte Therapies
Seattle, WA

John C. Gutheil, MD
Favrille Incorporated
San Diego, CA

Kristen Hege, MD
Cell Genesys
South San Francisco, CA

Steven Hirschfeld, MD, PhD
FDA Office of Cellular, Tissue and Gene Therapies
Rockville, MD

Axel Hoos, MD, PhD
Antigenics
Lexington, MA

Elizabeth M. Jaffee, MD
Johns Hopkins University
Baltimore, MD

Karin Jooss, PhD
Cell Genesys, Inc.
South San Francisco, CA

Howard L. Kaufman, MD
NY Presbyterian Hospital - Columbia Campus
New York, NY

Ulrich Keilholz, MD
Charité CBF
Berlin, Germany

Edward L. Korn
National Cancer Institute
Bethesda, MD

Stephen D. Litwin, MD
Biologics Consulting Group
Washington, DC

Ke Liu, MD
FDA, Office of Cellular, Tissue, Gene Therapies
Rockville, MD

Hans Loibner, PhD
HL Bioscience Research GmbH
Vienna, Austria

Michael T. Lotze, MD
Univ. of Pittsburgh, Molecular Medicine Inst.
Pittsburgh, PA

Kim A. Margolin, MD
City of Hope
Duarte, CA

Francesco Marincola, MD
NIH/CC/DTM
Bethesda, MD

Geoffrey Nichol, MD
Medarex, Inc
Bloomsbury, NJ

Marilyn Olson
Biomira Inc.
Edmonton, Canada

Dennis L. Panicali, PhD
Therion Biologics Corporation
Cambridge, MA

Giorgio Parmiani, MD
Istituto Nazionale Tumori
Milan, Italy

James Pingpank
National Cancer Institute
Bethesda, MD

Pedro J. Romero, MD
Ludwig Institute of Cancer Research Lausanne Branch
Lausanne, Switzerland

Natalie Sacks, MD
Cell Genesys, Inc.
San Francisco, CA

Michael Salgaller, PhD
Toucan Capital Corp.
Bethesda, MD

Bruce Scharschmidt, MD
Chiron Corporation
Emeryville, CA

Mario Sznol, MD
Yale University School of Medicine
New Haven, CT

Walter J. Urba, MD, PhD
Earle A. Chiles Research Institute
Portland, OR

Nicholas Van Baren
Ludwig Institute for Cancer Research
Brussels, Belgium

Johannes Vieweg, MD FACS
Duke University
Durham, NC

Barbara Winslow, PhD
CATO Research
San Diego, CA

Keith M. Wonnacott, PhD
FDA - Office of Cellular, Tissue, Gene Therapies
Rockville, MD